Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 29.82M P/E - EPS this Y - Ern Qtrly Grth -
Income -35.53M Forward P/E -1.09 EPS next Y - 50D Avg Chg 1.00%
Sales 48.54M PEG - EPS past 5Y - 200D Avg Chg 12.00%
Dividend N/A Price/Book 3.98 EPS next 5Y - 52W High Chg -58.00%
Recommedations 2.00 Quick Ratio 0.91 Shares Outstanding 29M 52W Low Chg 75.00%
Insider Own 4.57% ROA -26.76% Shares Float 11.78M Beta -0.67
Inst Own 66.89% ROE - Shares Shorted/Prior 81.71K/125.88K Price 1.07
Gross Margin 36.46% Profit Margin -73.21% Avg. Volume 1,122,283 Target Price 1.52
Oper. Margin -63.29% Earnings Date - Volume 28,969 Change 5.94%
About Centogene N.V.

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Centogene N.V. News
09/25/24 CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
08/19/24 Genetic testing in Parkinson’s disease patients: a standard of care imperative?
08/07/24 CENTOGENE Receives Delisting Notice From Nasdaq
08/01/24 CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
06/20/24 C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
05/31/24 CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
05/15/24 CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
05/15/24 CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
05/14/24 CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
05/10/24 CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
04/02/24 CENTOGENE Receives Nasdaq Non-Compliance Notice
03/19/24 CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
02/29/24 CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
02/28/24 CENTOGENE Explores Strategic Alternatives
02/28/24 CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
01/25/24 CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
01/24/24 CENTOGENE Receives French Research Tax Credit Accreditation
01/23/24 CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
01/18/24 CENTOGENE Announces Preliminary Full Year 2023 Revenue
12/19/23 CENTOGENE Announces Voting Results of Extraordinary General Meeting
CNTG Chatroom

User Image stocksdog Posted - 10 hours ago

$CNTG NR May 15, 2024 they were contemplating a transaction which to close July 15. Instead it is Q1 2025 that it will close. Difference of 6-9 months of losses is likely $0.50 per share. That said, the same NR spoke to cash profitability by end of this year.

User Image TJU Posted - 4 days ago

$CNTG Selling now is completely stupid. I'm waiting for my 20 cents to be paid out. As the company is even getting another loan, insolvency is not very likely.

User Image Energy2024 Posted - 1 week ago

$CNTG It is clear that Centogene must be challenged not only legally but also in the media to raise public awareness of its practices. Small investors should no longer be intimidated by the Expropriation Law and uncertainty, but instead, they must unite and fight for justice…

User Image Energy2024 Posted - 1 week ago

$CNTG These actions must not be tolerated. Small investors who have invested larger sums—such as 4,000 to 5,000 euros—and who have the financial means to fight back, should not be intimidated. Centogene is betting on the fact that these investors will not be able to defend themselves due to a lack of financial resources, but this is where the danger lies: if small investors do not act together and fight back, they will continue to be disadvantaged in this way. Therefore, it is crucial that those who have made substantial investments in Centogene and are now unjustly harmed speak out. There are legal avenues for taking action, and it is important to notify the relevant stock exchange regulators in Germany and across Europe. Additionally, legal pressure must be applied to force the company to take responsibility and face the consequences of its actions…

User Image Energy2024 Posted - 1 week ago

$CNTG Centogene AG: A Scandal Surrounding the Expropriation Law and the Strategy Behind the Conversion into a GmbH Centogene AG is systematically exploiting the Expropriation Law of 2021 to deceive and disadvantage small investors. This strategy involves converting from a public limited company (AG) to a GmbH and liquidating the company for a fraction of its true value, with small investors being the biggest losers. It is not only an unethical tactic but also one that is opaque and exploitative. What makes it even more problematic is that many crucial pieces of information were either disclosed too late or not at all. A simple example of this behavior is the EY audit note from 2022 and 2023, which confirmed that the company was no longer capable of continuing its operations. This is just one small example; there are many other pieces of evidence that paint Centogene’s actions in an even worse light..

User Image TJU Posted - 1 week ago

$CNTG The good news: business goes on. Good for the patients. The bad news is that the company is being sold off. Unless another buyer is found who makes an irresistible offer. Soon one million patient data. Curated. Patents. Biomarker AI. Three years ago, celebrated as the most innovative biotech company in Germany. Incomprehensible.

User Image Energy2024 Posted - 1 week ago

$CNTG Let’s join forces and take action against Centogene and those responsible. We should file a complaint with the financial regulatory authorities and insist that the case be thoroughly investigated. Whether or not we have a chance of success, it’s important that we speak up. The more of us who get involved, the stronger our cause will be. We need to make sure these wrongdoings are not left unpunished.

User Image Energy2024 Posted - 1 week ago

$CNTG I believe that Centogene committed fraud by selling the company for a bargain price—almost 9 million euros, which I consider a ridiculous amount. It seems likely that large investors were compensated internally, while small investors were left out and financially harmed. I am calling for European compliance authorities, financial regulators, and the public prosecutor to conduct a thorough investigation into the company and hold those responsible accountable. The former founder, Rolfes, should also be investigated, as this appears to be a massive fraud involving millions taken from small investors. I recommend that all affected small investors file complaints, even if the outcome is uncertain, to bring this injustice to light and seek possible consequences.

User Image stocksdog Posted - 1 week ago

$CNTG thought a low scenario would be a $1 exit. This is very disappointing 😤

User Image Energy2024 Posted - 1 week ago

$CNTG In my view, the decision by Centogene, described as “strategic,” may appear to be a significant loss for small shareholders. The terms negotiated by large investors such as Charme Capital and the Public Investment Fund seem to have been beneficial for them. These major investors seem to have safeguarded their interests internally, while the smaller shareholders are left with little to nothing. The company’s decision to liquidate and the potential for only a small payout could be incredibly disappointing for smaller investors, giving the impression that the larger investors secured far better conditions. For smaller shareholders, this situation feels like a betrayal, especially considering that decisions were likely made with the interests of larger investors in mind, leaving the smaller ones to bear the losses.

User Image Energy2024 Posted - 1 week ago

$CNTG 100% Scam Sorry

User Image Energy2024 Posted - 1 week ago

$CNTG GAME OVER https://www.otcmarkets.com/filing/html?id=17965006&guid=K_Y-kW5ugLu4MVh

User Image Energy2024 Posted - 1 week ago

$WGS 🚀🔥🚀 🔜 $CNTG CENTOGENE 🔥🚀

User Image Energy2024 Posted - 1 week ago

$CNTG

User Image Energy2024 Posted - 1 week ago

$CNTG It’s no longer professional how Centogene is handling the uncertainties. The board members are still unclear, and the CFO is only staying until the end of December. There are no half-year results or clear statements about the company’s future. The positive statements from May should finally be addressed. I want to know if the company has a future or not, and I’m demanding clear communication and transparency to restore trust..

User Image Energy2024 Posted - 1 week ago

$CNTG https://www.globenewswire.com/news-release/2024/11/11/2978087/0/en/Whole-Genome-and-Exome-Sequencing-Market-Research-2024-2033-Driving-Down-Costs-Enhancing-Patient-Outcomes-and-Influencing-Global-Healthcare-Policies.html

User Image Energy2024 Posted - 1 week ago

$CNTG Many investors, around ninety percent of them, currently feel uncertain and are unsure whether to expect positive signs for the future or face a total loss. There’s a strong sense of ambiguity and insecurity. Back when the IPO took place, a nominal value of twelve cents per share was set, and today the stock price matches that exact value. Whether this was a deliberate strategy is hard to say, but the company’s actions appear extremely unprofessional and untrustworthy at the moment.

User Image Energy2024 Posted - 2 weeks ago

$CNTG I’m curious to see how the situation at Centogene AG unfolds. In May, there were positive statements made about the company’s future, particularly regarding reaching the EBITDA breakeven point. However, if these statements are not backed up by concrete results, I would find that very unprofessional. I remain curious whether this will ultimately turn out to be a fraud or if Centogene can still manage to turn things around..

User Image Energy2024 Posted - 2 weeks ago

$CNTG In 2019, Centogene set the nominal value of its shares at 0.12 cents during its IPO, while the offering price was set at 14 euros. It seems very strange to me that the current share price is almost exactly aligned with that nominal value. It almost feels like a coincidence, and I wonder if it was planned this way or if it’s simply a result of market conditions. It certainly seems odd to me and makes me question the strategy behind it…

User Image Energy2024 Posted - 2 weeks ago

$CNTG I find it hard to understand why Centogene doesn’t update important information, like changes in their leadership team, on their website in a timely manner. For a company of this size and significance, I expect such details to be updated immediately. This behavior seems unprofessional and is difficult to justify, especially when even a small business with just five employees can make these updates faster. The slow response time and lack of transparency not only harm the company’s credibility but also raise questions about internal communication and organization..

User Image Energy2024 Posted - 2 weeks ago

$CNTG SC 13G investor with a large stake is advantageous for small investors because their passive role makes it harder to execute a sale or merger of the company. This means that such major changes are not easily carried out, providing small investors with additional stability and protection against unwanted takeovers.

User Image Energy2024 Posted - 2 weeks ago

$CNTG https://www.otcmarkets.com/filing/html?id=17947709&guid=l1Y-k6rtmHBJPch

User Image Energy2024 Posted - 2 weeks ago

$CNTG I think Donald Trump is good for the Future. I hope also for Centogene

User Image Energy2024 Posted - 2 weeks ago

$CNTG I find it unacceptable that Centogene AG has provided hardly any transparent information for investors since going public, which has been extremely unprofessional from the start. It’s alarming that the company concealed the EY auditors’ notes from twenty twenty-two and twenty twenty-three, which already indicated that Centogene was not viable as a business. Especially after the delisting, I expect clear statements about the current situation and future plans – whether there’s truly a path forward or if the end is near.

User Image Energy2024 Posted - 3 weeks ago

$CNTG Such developments may also be substantiated. Delistings are typically not just known one or two weeks in advance; they are prepared months ahead of time. I believe that insider knowledge could be influencing these decisions…

User Image Energy2024 Posted - 3 weeks ago

$CNTG a company in an extremely poor penny-stock situation would be removed from the portfolio, so it surprises me that they have increased their share count and the company remains in the portfolio. It could be that they find it easier to make such purchases officially in the NASDAQ realm, while they might not be allowed to buy as many shares in the OTC market. It also seems to me that the supervisory board members have started to realize that the situation could be developing positively. Otherwise, they wouldn’t stay in office for so long. Additionally, there were statements in May from the CEO that a growth of ten to fifteen percent is expected in the diagnostics sector and that there are record orders in the pharmaceutical sector. The CFO also mentioned that the company could potentially reach EBITDA break-even in two thousand twenty-four...

User Image Energy2024 Posted - 3 weeks ago

$CNTG I find the situation very unusual and have rarely seen a company in such a crisis moment holding multiple supervisory board members through short-term extensions while large investors like Akatis and the Public Investment Fund of Saudi Arabia are increasing their stakes just before a delisting. Normally, in such moments, leaders and investors tend to withdraw as confidence wanes and transparency decreases. What is particularly interesting is that during the second extension of the supervisory board members, a larger transaction took place, where the number of shares was high, but in the penny-stock realm, it isn’t worth much. The fact that Akatis Investment increased its share count shortly before the delisting, despite already experiencing a significant loss in value, is noteworthy. Typically,..

User Image Energy2024 Posted - 10/31/24

$CNTG I understand that the larger transaction on October twenty-third took place right before the deadline for the second extension. This, combined with the short-term third extension until November fourth, raises questions. It’s unclear whether this was an insider purchase, which adds further intrigue to the situation. Even though the amount isn’t high, the number of shares is significant and could indicate important developments or changes within the company. This is definitely noteworthy and could play a crucial role in the decisions made by the board members..

User Image Energy2024 Posted - 10/31/24

$CNTG I have never experienced a situation where board members announce their resignation and then repeatedly extend their terms on such short notice. At the end of September, three board members officially announced their resignations, but only two of them have since extended their terms multiple times—first until October fifteenth, then until October twenty-fourth, and now until November fourth. These repeated short-term extensions strike me as unusual and somewhat odd, and I am curious to see what developments will follow from this. https://www.otcmarkets.com/filing/html?id=17927177&guid=zeL-kahaujiDB3h

User Image Energy2024 Posted - 10/31/24

$CNTG $WGS Whole Genome 🧬 Sequencing with AI is the Future in the Medicine / Pharmaceutical Industry and more 🔥. Database’s/ Diagnostic 🧬🔥. I believe this is the next Big turnaround.CENTOGENE. ..

Analyst Ratings
HC Wainwright & Co. Buy Jun 28, 23
HC Wainwright & Co. Buy May 18, 23
HC Wainwright & Co. Buy Apr 27, 23
HC Wainwright & Co. Buy Apr 13, 23
HC Wainwright & Co. Buy Apr 12, 23
HC Wainwright & Co. Buy Feb 22, 23
HC Wainwright & Co. Buy Jan 17, 23
HC Wainwright & Co. Buy Nov 23, 22
SVB Leerink Outperform Jul 18, 22